Coldstream Capital Management Inc. Has $13.31 Million Stock Holdings in Johnson & Johnson $JNJ

Coldstream Capital Management Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 9.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 87,129 shares of the company’s stock after buying an additional 7,476 shares during the period. Coldstream Capital Management Inc.’s holdings in Johnson & Johnson were worth $13,309,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. GFG Capital LLC bought a new stake in shares of Johnson & Johnson in the second quarter worth about $35,000. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at about $48,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $52,000. Finally, Pandora Wealth Inc. acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $65,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

JNJ opened at $203.88 on Friday. The business’s 50-day simple moving average is $188.25 and its 200 day simple moving average is $171.67. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $206.94. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market capitalization of $491.21 billion, a PE ratio of 19.68, a PEG ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Bank of America upped their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Finally, Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.